Interstitial lung diseases (ILDs) are complex diseases with various courses where
personalized medicine is highly expected. Biomarkers are indicators of physiological …

Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic
sclerosis (SSc). We performed a systematic review to characterise the use and validation of …

Background Systemic sclerosis is a rare disabling autoimmune disease with few treatment
options. The efficacy and safety of tocilizumab, an interleukin 6 receptor-α inhibitor, was …

Objective. To identify predictors of poor prognosis in patients with systemic sclerosis (SSc)
associated with interstitial lung disease (ILD). Methods. Fifty patients with early-stage SSc …

Duchenne muscular dystrophy (DMD) is a fatal muscle-wasting disorder caused by
mutations in the Dystrophin gene and for which there is currently no cure. To bridge the gap …

Cardiac fibrosis is a pathological process associated with various forms of heart failure. This
study identified latent transforming growth factor-β binding protein 2, cartilage oligomeric …

Objectives Decision on treatment of systemic sclerosis (SSc) related interstitial lung disease
(ILD) largely relies on the findings on high resolution computed tomography (HRCT) and …

Background Skin fibrosis is a hallmark feature of systemic sclerosis. Skin biopsy
transcriptomics and blister fluid proteomics give insight into the local environment of the skin …

Idiopathic pulmonary fibrosis (IPF) is a progressive and life threatening disease with median
survival of 2.5–3 years. The IPF lung is characterized by abnormal lung remodeling …

Drug development for systemic sclerosis (SSc) benefits from understanding the relationship
between disease and circulating biomarkers to enable activities such as patient stratification …